{
  "module": "kr-companies",
  "itemId": "00137359",
  "title": "SHINPOONG PHARMACEUTICAL CO.,LTD (신풍제약(주)) — KOSPI 019170",
  "summary": "Korean listed company (신풍제약(주), KOSPI 019170). Official DART corporate profile, KRW financial summary, and recent filings.",
  "data": {
    "corp_code": "00137359",
    "stock_code": "019170",
    "name_en": "SHINPOONG PHARMACEUTICAL CO.,LTD",
    "name_ko": "신풍제약(주)",
    "alternate_names": [
      "신풍제약"
    ],
    "market": "KOSPI",
    "ceo_name": "유 제 만",
    "business_registration_no": "1348103819",
    "corporate_registration_no": "1301110011815",
    "address": "경기도 안산시 단원구 원시로 7",
    "homepage": "https://www.shinpoong.co.kr/",
    "established_date": "1986-07-23",
    "fiscal_month": "12",
    "industry_code": "212",
    "financials": {
      "fiscal_year": 2025,
      "basis": "CFS",
      "currency": "KRW",
      "revenue": 234680653227,
      "operating_income": 14255167972,
      "net_income": 8389168304,
      "total_assets": 352466324389,
      "total_liabilities": 81738685157,
      "total_equity": 270727639232,
      "prior_year": {
        "fiscal_year": 2024,
        "revenue": 221094069689,
        "operating_income": -20455432597,
        "net_income": -15373463449,
        "total_assets": 342092805074,
        "total_liabilities": 84002936786,
        "total_equity": 258089868288
      },
      "source_url": "https://dart.fss.or.kr/dsaf001/main.do?rcpNo=20260320000611",
      "verified_at": "2026-11-01T02:28:11.832Z"
    },
    "recent_filings": [
      {
        "receipt_no": "20261022800250",
        "filed_date": "2026-10-22",
        "title_ko": "투자판단관련주요경영사항              (급성 허혈성 뇌졸중 치료제 SP8203 임상 3상 시험변경계획 승인)",
        "title_en": "Material Business Matters Related to Investment Decisions              (급성 허혈성 뇌졸중 치료제 SP8203 임상 3상 시험변경계획 승인)",
        "filer": "신풍제약",
        "url": "https://dart.fss.or.kr/dsaf001/main.do?rcpNo=20261022800250"
      },
      {
        "receipt_no": "20260915800457",
        "filed_date": "2026-09-15",
        "title_ko": "투자판단관련주요경영사항              (급성 허혈성 뇌졸중 치료제 SP8203 임상 3상 시험변경계획 승인 신청)",
        "title_en": "Material Business Matters Related to Investment Decisions              (급성 허혈성 뇌졸중 치료제 SP8203 임상 3상 시험변경계획 승인 신청)",
        "filer": "신풍제약",
        "url": "https://dart.fss.or.kr/dsaf001/main.do?rcpNo=20260915800457"
      },
      {
        "receipt_no": "20260814003040",
        "filed_date": "2026-08-14",
        "title_ko": "반기보고서 (2026.06)",
        "title_en": "Semi-annual Report (2026.06)",
        "filer": "신풍제약",
        "url": "https://dart.fss.or.kr/dsaf001/main.do?rcpNo=20260814003040"
      }
    ],
    "source_urls": {
      "company": "https://dart.fss.or.kr",
      "financials": "https://dart.fss.or.kr/dsaf001/main.do?rcpNo=20260320000611",
      "filings": "https://dart.fss.or.kr/dsaf001/main.do?rcpNo=20261022800250"
    },
    "source_url": "https://dart.fss.or.kr/dsaf001/main.do?rcpNo=20260320000611",
    "verified_at": "2026-11-01T02:18:48.871Z",
    "notice": "Data from Korea's Financial Supervisory Service (DART) and National Tax Service. FSS does not guarantee accuracy or completeness. Figures in KRW as filed. Not investment advice. English names are as registered with DART and may differ from the Korean legal name. Use corp_code, stock_code, or business registration number to identify a company."
  },
  "source_url": "https://dart.fss.or.kr/dsaf001/main.do?rcpNo=20260320000611",
  "verified_at": "2026-11-01T02:18:48.871Z",
  "updated_at": "2026-11-01T02:18:48.871Z",
  "notice": "Data from Korea's Financial Supervisory Service (DART) and National Tax Service. FSS does not guarantee accuracy or completeness. Figures in KRW as filed. Not investment advice. English names are as registered with DART and may differ from the Korean legal name. Use corp_code, stock_code, or business registration number to identify a company."
}